Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ivermectin added to routine treatment for mild to moderate COVID-19
IRCT20180922041089N4Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of ivermectin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Improvement in clinical symptoms, Length of hospitalization and 3 more. Started Apr 2020; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20180922041089N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180922041089N4.